Pharmaceuticals

Universe Pharmaceuticals

Universe Pharmaceuticals released FY2025 Q2 earnings on July 3 Post-Market (EST), actual revenue USD 4.576 M, actual EPS USD -4.722

Universe Pharmaceuticals released FY2025 Q1 earnings on July 3 (EST), actual revenue USD 4.576 M, actual EPS USD -4.722

Earnings report released on July 3, 2025 (BJT) with actual revenue of USD 9.153 M and actual EPS of USD -9.4439

Universe Pharmaceuticals released FY2024 Q3 earnings on April 29 (EST), actual revenue USD 5.07 M, actual EPS USD 100.4953

Universe Pharmaceuticals released FY2024 Q4 earnings on April 29 (EST), actual revenue USD 5.07 M, actual EPS USD 100.4953

Universe Pharmaceuticals released FY2024 9 Months Earnings on April 29 (EST), with actual revenue of USD 17.95 M and EPS of USD 100.4953

Universe Pharmaceuticals released FY2024 Annual Earnings on April 29, 2025 (EST), with actual revenue of USD 23.02 M and EPS of USD -626.961

Nature's Bio Pharma Sales Decrease in FY2024

Universe Pharmaceuticals released FY2024 semi-annual earnings on September 20 (EST) with actual revenue of 12.88 M USD and EPS of 0 USD

Universe Pharmaceuticals released FY2024 Q1 earnings on September 20 (EST), with actual revenue of 6.442 M USD and EPS of 0 USD

Universe Pharmaceuticals released FY2024 Q2 earnings on September 20 (EST) with actual revenue of 6.442 M USD and EPS of 0 USD

Universe Pharmaceuticals released FY2023 Q4 earnings on January 30, 2024 (EST), with actual revenue of USD 6.921 M and EPS of USD 0

Universe Pharmaceuticals released FY2023 9 Months Earnings on January 30, 2024 (EST), with actual revenue of USD 25.39 M and EPS of USD 0

Universe Pharmaceuticals released FY2023 Q3 earnings on January 30, 2024 (EST) with actual revenue of USD 6.921 M and EPS of USD 0

Universe Pharmaceuticals released FY2023 earnings on January 30, 2024 (EST), actual revenue USD 32.31 M, actual EPS USD 0

Universe Pharmaceuticals released FY2023 Q2 earnings on August 31 (EST), with actual revenue of 9.234 M USD and EPS of 0 USD

Universe Pharmaceuticals released FY2023 Q1 earnings on August 31 (EST), actual revenue 9.234 M USD, actual EPS 0 USD

Universe Pharmaceuticals released FY2023 Semi-Annual Earnings on August 31 (EST), with actual revenue of 18.47 M USD and EPS of 0 USD

Universe Pharmaceuticals released FY2022 Q3 earnings on February 10, 2023 (EST), with actual revenue of 7.97 M USD and EPS of 0 USD

Universe Pharmaceuticals released FY2022 9 Months Earnings on February 10, 2023 (EST) with actual revenue of 32.17 M USD and EPS of 0 USD

Sobr Safe

Omeros

Northann

AMC Robotics

Euda Health

Dynavax Tech

Multi Ways

Indaptus Therapeutics

Sidus Space

Kandal M Venture

Eli Lilly

Roche

ROCHE HOLDINGS AG

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap